Iovance Biotherapeutics: Amtagvi grows by 68% – Lung cancer opens seven times larger market opportunity

Iovance is developing TIL cell therapies for solid tumors and already markets an approved therapy for advanced melanoma with Amtagvi. For lung cancer, Lifileucel addresses a potentially about seven times larger US market. Important study data is expected in the 4th quarter. In the 2nd quarter, revenue increased by 66%, while a further opportunity with a response rate of 50% has emerged for soft tissue sarcomas. Iovance Biotherapeutics (IOVA) develops personalized TIL cell therapies for various solid tumors. This involves expanding and...